Clinical Trial Update: Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating nafamostat mesylate for anticoagulation during VV-ECMO in critical illness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness

Drugs mentioned

• Nafamostat Mesylate (nafamostat)

Snippet

Sponsor: Xiaobo Yang, MD | Conditions: Critical Illness, Anticoagulation | Phase 2 | Status: UNKNOWN